Contact
searchSearch
HMP Global
Login
Lajos Pusztai, MD, DPhil
Videos
T-DXd Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/19/2026
Lajos Pusztai, MD, DPhil
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil,...
05/19/2026
Oncology
News
BTX-9341 Shows Promising Efficacy, Safety in HR-Positive, HER2-Negative Advanced Breast Cancer
05/15/2026
Emily Estrada
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1 BTX-9341-101 trial demonstrated that BTX-9341 shows encouraging efficacy and safety in heavily pretreated patients with HR-positive, HER2-negative advanced or metastatic breast cancer.
Results from the phase 1...
05/15/2026
Oncology
News
pCR Guided Chemotherapy De-Escalation Shows Promise in HER2-Positive Early Breast Cancer
05/15/2026
Emily Estrada
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided strategy with dual HER2 blockade achieved high response rates and preserved quality of life in patients with HER2-positive early breast cancer.
A chemotherapy-free, pCR-guided...
05/15/2026
Oncology
News
Tucatinib Plus T-DM1 Shows Sustained Disease Control in HER2-Positive Advanced Breast Cancer
05/13/2026
Emily Estrada
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3 HER2CLIMB-02 trial demonstrated that tucatinib plus T-DM1 improved PFS in patients with HER2-Positive locally advanced or metastatic breast cancer, including those with brain metastases.
Final results from the phase 3...
05/13/2026
Oncology
News
Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/11/2026
Stephanie Holland
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...
Post hoc analysis results from...
05/11/2026
Oncology
News
Sacituzumab Govitecan Plus Trastuzumab Showed Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer
05/11/2026
Stephanie Holland
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.
According to results from the...
05/11/2026
Oncology
Paolo Tarantino, MD
Videos
Sacituzumab Govitecan Demonstrates Limited Activity Following T-DXd in HER2-Positive Metastatic Breast Cancer
05/07/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses...
05/07/2026
Oncology
News
Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer
05/07/2026
Stephanie Holland
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.
Results from the phase 2...
05/07/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use